| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 2.1 | 0.0 |
| Net income | -44.5 | -33.5 |
| EPS (diluted, $ a share) | $-0.36 | $-21.66 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: PBLS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Parabilis Medicines, Inc.: key numbers
- Share price
- $28.45Close, Nov 16
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Parabilis Medicines, Inc.
All →Parabilis Medicines Financial Results
Parabilis Medicines reported third-quarter 2026 financial results, ending the period with $1.1 billion in cash and marketable securities. The company reached alignment with the FDA on the Phase 3 registrational trial design for zolucatetide in desmoid tumors, with initiation planned for the first half of 2027. Additionally, the company entered a clinical collaboration with Revolution Medicines to evaluate zolucatetide in combination therapies for metastatic colorectal cancer.
- Term
- Q3 2026
“With each successive clinical update, we are building a stronger foundation for zolucatetide as a unique medicine with the potential to make a meaningful difference for patients across multiple diseases.”
Mathai Mammen, M.D., Ph.D., Chairman, Chief Executive Officer and President
“The progress across our portfolio continues to strengthen our conviction in the ability of our Helicon platform to repeatedly translate breakthrough science into medicines that can meaningfully improve patients’ lives.”
Mathai Mammen, M.D., Ph.D., Chairman, Chief Executive Officer and President
Parabilis Medicines Capacity Expansion
Parabilis Medicines entered into a lease amendment to expand its corporate headquarters in Cambridge, Massachusetts, by 33,525 square feet. The agreement also extends the existing lease term from March 2031 through December 2037 and includes options for two additional five-year extensions.
- Counterparty
- LS 400/500 CDP, LLC
- Term
- through Dec 2037